Harmony Advances Pitolisant GR After Bioequivalence Success
Positive trial results position the next-generation pitolisant formulation for a New Drug Application in early 2026.
Read MorePositive trial results position the next-generation pitolisant formulation for a New Drug Application in early 2026.
Read MoreIt will launch in early 2026 in a limited US beta version.
Read MoreThe company is phasing in a rebrand that emphasizes continuity with its legacy while positioning its portfolio for global partnerships and potential deals.
Read MoreNew findings serve to update a broader hypothesis that has been in development at WSU for years—proposing that sleep arises from communication between the body’s sleep regulatory systems and the multitude of microbes living inside us.
Read MoreAn international study of nearly 700 people with this Parkinson’s precursor finds dramatically reduced cortical thinning in women and links the protection to estrogen-related gene activity.
Read More